An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

This study will evaluate the safety and efficacy of omalizumab for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with Cystic Fibrosis aged 12 years and older.

Critère d'inclusion

Cystic fibrosis,Allergic Bronchopulmonary Aspergillosis

Liens

nct
ictrp